NASDAQ$BLTE
Belite Bio Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Belite Bio reported increased research and development expenses and a higher net loss in Q4 2024.
Belite Bio's Q4 2024 net loss widened to $10.1 million due to increased R&D expenses related to its clinical trials. The company did not generate revenue, as it remains in the development stage. Cash and investments totaled $145.2 million, providing runway for ongoing trials. The pivotal Phase 3 DRAGON trial continues as planned, with completion expected in Q4 2025.
- Belite Bio reported a Q4 2024 net loss of $10.1 million, compared to $7.0 million in Q4 2023.
- R&D expenses increased to $7.3 million, up from $4.9 million in Q4 2023, due to trial progress.
- The company raised $15 million in a direct offering to support clinical development.
- Cash and investments totaled $145.2 million, ensuring funding for ongoing trials.
Headline financials
Revenue & EPS history
Belite Bio · Revenue · Quarterly
$0
Forward guidance
Belite Bio remains focused on advancing its clinical pipeline, with completion of key trials expected in late 2025.
Tailwinds
- Phase 3 DRAGON trial remains on track with no modifications recommended.
- Enrollment in the PHOENIX trial for geographic atrophy increased to 406 subjects.
- Sufficient cash and investments to fund operations through key milestones.
- Potential additional $15 million in proceeds from warrant exercises.
- Continued regulatory engagement for Tinlarebant’s approval pathway.
Headwinds
- No revenue generation as the company remains in the development stage.
- R&D expenses continue to rise with trial progress, increasing cash burn.
- Dependence on external funding to support long-term operations.
- Regulatory uncertainties in securing approvals across global markets.
- Potential delays in clinical trial completion due to enrollment challenges.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q4 2024
+0.3%
Avg return
Earnings day
+4.6%
Avg return
5 days after
+3.1%
Avg return
30 days after
31%
4 / 13 earnings
Positive
+36.6%
Q2 2022
Best reaction
-15.2%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -6.5% | — | — | |
| Q1 2025 | -3.4% | +3.9% | +0.2% | |
| Q4 2024 | +0.5% | -0.2% | -15.1% | |
| Q3 2024 | +4.6% | +5.3% | -19.4% | |
| Q2 2024 | -1.4% | +1.3% | -2.1% | |
| Q1 2024 | -0.1% | +6.9% | +18.8% | |
| Q4 2023 | -15.2% | -16.5% | -13.6% | |
| Q3 2023 | -3.7% | -5.4% | +12.3% | |
| Q2 2023 | +2.3% | +4.2% | +39.9% | |
| Q4 2022 | -3.4% | -1.2% | -1.9% | |
| Q4 2020 | -3.4% | -1.2% | -1.9% | |
| Q4 2021 | -3.4% | -1.2% | -1.9% | |
| Q2 2022 | +36.6% | +59.4% | +21.7% | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro